Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Hepatocellular Carcinoma | Research article

Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma

Authors: Hui Li, Yujuan Liu, Wei Jiang, Junhui Xue, Yuning Cheng, Jiyin Wang, Ruixiang Yang, Xiaowei Zhang

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Icaritin, an active ingredient of the Chinese herb Epimedium, plays an anti-tumor role in liver cancer by inhibiting the proliferation of hepatocellular cells and promoting their apoptosis. In China, phase II and a large phase III clinical trial of icaritin reagent for the treatment of hepatocellular cancer is under-going, but the specific mechanism of icaritin action was unclear. Alpha-fetoprotein (AFP), an oncofetal protein, produced in the healthy fetal liver and yolk sac. Intracellular AFP promoted cellular proliferation and inhibited cellular apoptosis in hepatocellular carcinoma (HCC). The study was aimed to investigate the effect of icaritin on HCC through p53/AFP pathway.

Methods

Real-time RT PCR and western blot were used to detect p53 and AFP expression levels in HCC cells treated with icaritin. The mechanism of icaritin affecting p53 expression was verified by ubiquitination experiment, and the binding activity of icaritin on p53 in AFP promoter region was verified by luciferase experiment. EdU, MTT and flow cytometry were used to determine whether icaritin affected HCC cellular proliferation and apoptosis through p53/ AFP pathway. Expression levels of p53 and AFP in xenograft mouse model were determined by western blotting.

Results

Our results showed icaritin inhibited AFP expression at mRNA and protein level. AFP was also identified as the target gene of the p53 transcription factor. Icaritin abrogated murine double minute (Mdm) 2-mediated p53 ubiquitination degradation to improve the stability of p53. Up-regulated p53 protein levels then transcriptionally inhibited the AFP promoter. Icaritin-mediated decrease of AFP through Mdm2/p53 pathways inhibited HCC cellular proliferation and promoted HCC cellular apoptosis.

Conclusion

Our findings revealed the mechanism of icaritin in promoting apoptosis and inhibiting proliferation in liver cancer cells. The regulatory mechanism of icaritin in AFP protein down-regulation provides a theoretical and experimental basis for further research into new drugs for the treatment of liver cancer.

Available only for authorised users

Wang X, Wang Q. Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity. Can J Gastroenterol Hepato. 2018;2018:9049252–8. https://doi.org/10.1155/2018/9049252.CrossRef

Sauzay C, Petit A, Bourgeois AM, Barbare JC, Chauffert B, Galmiche A, Houessinon A. (2016) alpha-foetoprotein (AFP): a multi-purpose marker in hepatocellular carcinoma. Clin Chim Acta. 2016;463:39–44. https://doi.org/10.1016/j.cca.2016.10.006.CrossRefPubMed

Mizejewski GJ. Therapeutic use of human alpha-fetoprotein in clinical patients: is a cancer risk involved? Int J Cancer. 2011;128(1):239–49. https://doi.org/10.1002/ijc.25292.CrossRefPubMed

Yang X, Chen L, Liang Y, Si R, Jiang Z, Ma B, et al. Knockdown of alpha-fetoprotein expression inhibits HepG2 cell growth and induces apoptosis. J Cancer Res Ther. 2018;14(10):634–43. https://doi.org/10.4103/0973-1482.180681.CrossRef

Li MS, Li H, Li CY, Zhou S, Guo YL, Liu H, et al. Alpha fetoprotein is a novel protein-binding partner for caspase-3 and blocks the apoptotic signaling pathway in human hepatoma cells. Int J Cancer. 2009;124(12):2845–54. https://doi.org/10.1002/ijc.24272.CrossRefPubMed

Li MS, Li H, Li CY, Wang SS, Jiang W, Zhou S, et al. Alpha-fetoprotein, a new member of intracellular signal molecules in regulation of the PTEN/AKT signaling in human hepatoma cells lines. Int J Cancer. 2011;128(3):524–32. https://doi.org/10.1002/ijc.25373.CrossRefPubMed

Li CY, Wang SS, Jiang W, Li H, Liu ZM, Zhang C, McNutt MA, Li G. Impact of intracellular alpha fetoprotein on retinoic acid receptors-mediated expression of GADD153 in human hepatoma cell lines. Int J Cancer. 2012;130(4):754–64. https://doi.org/10.1002/ijc.26025.CrossRefPubMed

Wang SS, Jiang W, Chen XM, Zhang C, Li H, Hou WT, Liu Z, McNutt MA, Lu F, Li G. Alpha-fetoprotein acts as a novel signal molecule and mediates transcription of Fn14 in human hepatocellular carcinoma. J Hepatol. 2012;57(2):322–9. https://doi.org/10.1016/j.jhep.2012.03.029.CrossRefPubMed

Li Z, Wang XP, Lin HP, Xu B, Zhao Q, Qi BN, et al. (2015) anti-tumor immunity elicited by cross-linking vaccine heat shock protein 72 and alpha-fetoprotein epitope peptide. Neoplasma. 2015;62(5):713–21. https://doi.org/10.4149/neo_2015_085.CrossRefPubMed

10.

Qian ZQ, Wang YW, Li YL, Li YQ, Ling Z, Yang DL. (2017) Icariin prevents hypertension-induced cardiomyocyte apoptosis through the mitochondrial apoptotic pathway. Biomed Pharmacother. 2017;88:823-831, doi: https://doi.org/10.1016/j.biopha.2017.01.147.

11.

Zhou JM, Wu JF, Chen XH, Fortenbery N, Eksioglu E, Kodumudi KN, PK EB, Dong J, Djeu JY, Wei S. Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions. Int Immunopharmacol. 2011;11(7):890–8. https://doi.org/10.1016/j.intimp.2011.01.007.CrossRefPubMed

12.

Li CR, Li Q, Mei QB, Lu TL. Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in Herba Epimedii. Life Sci. 2015;126:57–68. https://doi.org/10.1016/j.lfs.2015.01.006.CrossRefPubMed

13.

Guo YM, Zhang XT, Meng J, Wang ZY. An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur J Pharmacol. 2011;658(2–3):114–22. https://doi.org/10.1016/j.ejphar.2011.02.005.CrossRefPubMedPubMedCentral

14.

Li HC, Liang QH, Wang L. Icaritin inhibits glioblastoma cell viability and glycolysis by blocking the IL-6/Stat3 pathway. J Cell Biochem. 2018;120(5):7257–64. https://doi.org/10.1002/jcb.28000.CrossRef

15.

Li ZJ, Yao C, Liu SF, Chen L, Xi YM, Zhang W, Zhang GS. Cytotoxic effect of icaritin and its mechanisms in inducing apoptosis in human burkitt lymphoma cell line. Biomed Res Int. 2014;2014:391512–7. https://doi.org/10.1155/2014/391512.CrossRefPubMedPubMedCentral

16.

Lim RZL, Li L, Chew N, Yong EL. The prenylflavonoid Icaritin enhances osteoblast proliferation and function by signal transducer and activator of transcription factor 3 (STAT-3) regulation of C-X-C chemokine receptor type 4 (CXCR4) expression. Bone. 2017;105:122–33. https://doi.org/10.1016/j.bone.2017.08.028.CrossRefPubMed

17.

Gao LF, Chen M, Ouyang Y, Li RB, Zhang X, Gao XS, Lin S, Wang X. Icaritin induces ovarian cancer cell apoptosis through activation of p53 and inhibition of Akt/mTOR pathway. Life Sci. 2018;202:188–94. https://doi.org/10.1016/j.lfs.2018.03.059.CrossRefPubMed

18.

He J, Wang Y, Duan F, Jiang H, Chen MF, Tang SY. Icaritin induces apoptosis of HepG2 cells via the JNK1 signaling pathway independent of the estrogen receptor. Planta Med. 2010;76(16):1834–9. https://doi.org/10.1055/s-0030-1250042.CrossRefPubMed

19.

Zhao H, Guo YM, Li S, Han RQ, Ying JM, Zhu H, et al. A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway. Oncotarget. 2015;6(11):31927–43. https://doi.org/10.18632/oncotarget.5578.CrossRefPubMedPubMedCentral

20.

Rong Y, Tu YF, Yin TJ, Meng ZY, Dou GF, Hu M. Rapid intestinal glucuronidation and hepatic glucuronide recycling contributes significantly to the enterohepatic circulation of icaritin and its glucuronides in vivo. Arch Toxicol. 2020;94(11):3737–49. https://doi.org/10.1007/s00204-020-02867-3.CrossRefPubMed

21.

Zhang C, Li H, Jiang W, Zhang XW, Li G. Icaritin inhibits the expression of alpha-fetoprotein in hepatitis B virus-infected hepatoma cell lines through post-transcriptional regulation. Oncotarget. 2016;7(50):83755–66. https://doi.org/10.18632/oncotarget.13194.CrossRefPubMedPubMedCentral

22.

Yang DL, Yao MJ, Yan Y, Liu YN, Wen XJ, Chen XM, Lu FM. Deoxycholic acid Upregulates serum Golgi protein 73 through activating NF-κB pathway and destroying Golgi structure in liver disease. Biomolecules. 2021;11(2):205. https://doi.org/10.3390/biom11020205.CrossRefPubMedPubMedCentral

23.

Chen YF, Pan KW, Wang PZ, Cao ZY, Wang WB, Wang SY, Hu N, Xue J, Li H, Jiang W, Li G, Zhang X. HBP1-mediated regulation of p21 protein through the Mdm2/p53 and TCF4/EZH2 pathways and its impact on cell senescence and tumorigenesis. J Biol Chem. 2016;291(24):12688–705. https://doi.org/10.1074/jbc.M116.714147.CrossRefPubMedPubMedCentral

24.

Lee KC, Crowe AJ, Barton MC. p53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding. Mol Cell Biol. 1999;19(12):1279–88. https://doi.org/10.1128/mcb.19.2.1279.CrossRefPubMedPubMedCentral

25.

Ghouri YA, Mian I, Rowe .H. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog 2017;16(1):4109–4116. doi: https://doi.org/10.4103/jcar.JCar_9_16.

26.

Kudo M. Systemic therapy for hepatocellular carcinoma: 2017 update. Oncolog. 2017;93(Suppl 1):135–46. https://doi.org/10.1159/000481244.CrossRef

27.

Daher S, Massarwa M, Benson AA, Khoury T. Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. J Clin Transl Hepatol. 2018;6(1):1–10. https://doi.org/10.14218/JCTH.2017.00031.CrossRef

28.

Nakabayashi H, WatanabeS K, Saitos A, Otsurull A, Sawadaishill K, Tamaoki T. Transcriptional regulation of a-fetoprotein expression by dexamethasone in human Hepatoma cells. J Biol Chem. 1989;264(1):266–71. https://doi.org/10.1016/S0021-9258(17)31253-X.CrossRefPubMed

29.

Xie ZF, Zhang H, Tsai WW, Zhang Y, Du Y, Zhong JG, et al. Zinc finger protein ZBTB20 is a key repressor of alpha-fetoprotein gene transcription in liver. Proc Natl Acad Sci. 2008;105(31):10859–64. https://doi.org/10.1073/pnas.0800647105.CrossRefPubMed

30.

Nakabayashi H, Hashimoto T, Miyao Y, Tjong KK, Chan J, Tamaoki TA. Position-dependent silencer plays a major role in repressing a-fetoprotein expression in human Hepatoma. Mol Cell Biol. 1991;11(12):5885–93. https://doi.org/10.1128/mcb.11.12.5885.CrossRefPubMedPubMedCentral

31.

Kruse JP, Gu W. (2009) modes of p53 regulation. Cell. 2009;137(4):609–22. https://doi.org/10.1016/j.cell.2009.04.050.CrossRefPubMedPubMedCentral

32.

Bailly C. Molecular and cellular basis of the anticancer activity of the prenylated flavonoid icaritin in hepatocellular carcinoma. Chem Biol Interact. 2020;25:109124. https://doi.org/10.1016/j.cbi.2020.109124.CrossRef

33.

Wang SK, Wang Q, Wang HJ, Qin CK, Cui XP, Li L, Liu Y, Chang H. Induction of ROS and DNA damage-dependent senescence by icaritin contributes to its antitumor activity in hepatocellular carcinoma cells. Pharma Bio. 2019;57(1):423–31. https://doi.org/10.1080/13880209.2019.1628073.CrossRef

Title: Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma
Authors: Hui Li
Yujuan Liu
Wei Jiang
Junhui Xue
Yuning Cheng
Jiyin Wang
Ruixiang Yang
Xiaowei Zhang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08043-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Impacts of the SOAT1 genetic variants and protein expression on HBV-related hepatocellular carcinoma

Clinical outcomes observation in stage IIB–IIIB cervical cancer treated by adjuvant surgery following concurrent chemoradiotherapy

Clinical characteristics and risk factors associated with Pneumocystis jirovecii infection in patients with solid tumors: study of thirteen-year medical records of a large cancer center

PCNA-associated factor (KIAA0101/PCLAF) overexpression and gene copy number alterations in hepatocellular carcinoma tissues

Tumor volume: a new prognostic factor of oncological outcome of localized clear cell renal cell carcinoma

Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway

Keynote webinar | Spotlight on antibody–drug conjugates in cancer